Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction of Tipranavir and Ritonavir With Loperamide
NCT02251119Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2002
- Primary completion
- Jan 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum decrease in the percentage baseline CO2 response slope at Day 22 and Zero-to-six hour area under the curve for the percentage baseline CO2 response slope profile at Day 22. Started Jul 2002; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02251119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251119.